Open AccessSingle‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study
Author(s) -
Watson Sarah,
Verret Benjamin,
Ropert Stanislas,
Adam Julien,
Bahleda Rastislav,
Briand Sylvain,
Cavalcanti Andrea,
Chamseddine Ali N.,
Court Charles,
Fadel Elie,
Faron Matthieu,
HaddagMiliani Leila,
He Clémence,
Pechoux Cécile Le,
Levy Antonin,
Mercier Olaf,
Ngo Carine,
Honoré Charles,
Cesne Axel Le,
Mir Olivier
Publication year - 2023
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.5147
Subject(s) - angiosarcoma , gemcitabine , medicine , pazopanib , medical record , oncology , retrospective cohort study , deoxycytidine , chemotherapy , surgery , cancer , sunitinib
Abstract Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single‐agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single‐agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI‐CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1–6.5), and median OS was 9.9 months (95%CI: 6.6–13.4). Single‐agent gemcitabine has clinically meaningful activity in advanced, heavily pre‐treated angiosarcoma.